The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis

被引:48
作者
Stover, Daniel G. [1 ,2 ]
Coloff, Jonathan L. [2 ]
Barry, William T. [3 ]
Brugge, Joan S. [2 ]
Winer, Eric P. [1 ]
Selfors, Laura M. [2 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 12, Boston, MA 02115 USA
[2] Harvard Med Sch, Dept Cell Biol, 240 Longwood Ave,C501, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA
关键词
TUMOR-INFILTRATING LYMPHOCYTES; MOLECULAR SUBTYPES; SURVIVAL; PROGNOSIS; PREDICTOR; PACLITAXEL; SIGNATURES; PROFILES; PATTERNS; BENEFIT;
D O I
10.1158/1078-0432.CCR-16-0471
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To provide further insight into the role of proliferation and other cellular processes in chemosensitivity and resistance, we evaluated the association of a diverse set of gene expression signatures with response to neoadjuvant chemotherapy (NAC) in breast cancer. Experimental Design: Expression data from primary breast cancer biopsies for 1,419 patients in 17 studies prior to NAC were identified and aggregated using common normalization procedures. Clinicopathologic characteristics, including response to NAC, were collected. Scores for 125 previously published breast cancer-related gene expression signatures were calculated for each tumor. Results: Within each receptor-based subgroup or PAM50 subtype, breast tumors with high proliferation signature scores were significantly more likely to achieve pathologic complete response to NAC. To distinguish "proliferation-associated" from "proliferation-independent" signatures, we used correlation and linear modeling approaches. Most signatures associated with response to NAC were proliferation associated: 90.5% (38/42) in ER+/HER2(-) and 63.3% (38/60) in triple-negative breast cancer (TNBC). Proliferation-independent signatures predictive of response to NAC in ER+/HER2(-) breast cancer were related to immune activity, while those in TNBC comprised a diverse set of signatures, including immune, DNA damage, signaling pathways (PI3K, AKT, Ras, and EGFR), and "stemness" phenotypes. Conclusions: Proliferation differences account for the vast majority of predictive capacity of gene expression signatures in neoadjuvant chemosensitivity for ER+/HER2(-) breast cancers and, to a lesser extent, TNBCs. Immune activation signatures are proliferation-independent predictors of pathologic complete response in ER+/HER2(-) breast cancers. In TNBCs, significant proliferation-independent signatures include gene sets that represent a diverse set of cellular processes. (C)2016 AACR.
引用
收藏
页码:6039 / 6050
页数:12
相关论文
共 56 条
  • [1] Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer
    Andre, F
    Khalil, A
    Slimane, K
    Massard, C
    Mathieu, MC
    Vignot, S
    Assi, H
    Delaloge, S
    Spielmann, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) : 2996 - 3000
  • [2] Ki67-no evidence for its use in node-positive breast cancer
    Andre, Fabrice
    Arnedos, Monica
    Goubar, Aicha
    Ghouadni, Amal
    Delaloge, Suzette
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2015, 12 (05) : 296 - 301
  • [3] Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
    Balko, Justin M.
    Giltnane, Jennifer M.
    Wang, Kai
    Schwarz, Luis J.
    Young, Christian D.
    Cook, Rebecca S.
    Owens, Phillip
    Sanders, Melinda E.
    Kuba, Maria G.
    Sanchez, Violeta
    Kurupi, Richard
    Moore, Preston D.
    Pinto, Joseph A.
    Doimi, Franco D.
    Gomez, Henry
    Horiuchi, Dai
    Goga, Andrei
    Lehmann, Brian D.
    Bauer, Joshua A.
    Pietenpol, Jennifer A.
    Ross, Jeffrey S.
    Palmer, Gary A.
    Yelensky, Roman
    Cronin, Maureen
    Miller, Vincent A.
    Stephens, Phillip J.
    Arteaga, Carlos L.
    [J]. CANCER DISCOVERY, 2014, 4 (02) : 232 - 245
  • [4] Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
    Burcombe, Russell
    D Wilson, George
    Dowsett, Mitch
    Khan, Ifty
    Richman, Paul I.
    Daley, Frances
    Detre, Simone
    Makris, Andreas
    [J]. BREAST CANCER RESEARCH, 2006, 8 (03)
  • [5] Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Carey, Lisa A.
    Perou, Charles M.
    Livasy, Chad A.
    Dressler, Lynn G.
    Cowan, David
    Conway, Kathleen
    Karaca, Gamze
    Troester, Melissa A.
    Tse, Chiu Kit
    Edmiston, Sharon
    Deming, Sandra L.
    Geradts, Joseph
    Cheang, Maggie C. U.
    Nielsen, Torsten O.
    Moorman, Patricia G.
    Earp, H. Shelton
    Millikan, Robert C.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21): : 2492 - 2502
  • [6] Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer
    Chakravarthy, AB
    Kelley, MC
    McLaren, B
    Truica, CI
    Billheimer, D
    Mayer, IA
    Grau, AM
    Johnson, DH
    Simpson, JF
    Beauchamp, RD
    Jones, C
    Pietenpol, JA
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (05) : 1570 - 1576
  • [7] TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer
    Chen, Xi
    Li, Jiang
    Gray, William
    Lehmann, Brian
    Bauer, Joshua
    Shyr, Yu
    Pietenpol, Jennifer
    [J]. CANCER INFORMATICS, 2012, 11 : 147 - 156
  • [8] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, Patricia
    Zhang, Lijun
    Untch, Michael
    Mehta, Keyur
    Costantino, Joseph P.
    Wolmark, Norman
    Bonnefoi, Herve
    Cameron, David
    Gianni, Luca
    Valagussa, Pinuccia
    Swain, Sandra M.
    Prowell, Tatiana
    Loibl, Sibylle
    Wickerham, D. Lawrence
    Bogaerts, Jan
    Baselga, Jose
    Perou, Charles
    Blumenthal, Gideon
    Blohmer, Jens
    Mamounas, Eleftherios P.
    Bergh, Jonas
    Semiglazov, Vladimir
    Justice, Robert
    Eidtmann, Holger
    Paik, Soonmyung
    Piccart, Martine
    Sridhara, Rajeshwari
    Fasching, Peter A.
    Slaets, Leen
    Tang, Shenghui
    Gerber, Bernd
    Geyer, Charles E., Jr.
    Pazdur, Richard
    Ditsch, Nina
    Rastogi, Priya
    Eiermann, Wolfgang
    von Minckwitz, Gunter
    [J]. LANCET, 2014, 384 (9938) : 164 - 172
  • [9] GeneSigDB: a manually curated database and resource for analysis of gene expression signatures
    Culhane, Aedin C.
    Schroeder, Markus S.
    Sultana, Razvan
    Picard, Shaita C.
    Martinelli, Enzo N.
    Kelly, Caroline
    Haibe-Kains, Benjamin
    Kapushesky, Misha
    St Pierre, Anne-Alyssa
    Flahive, William
    Picard, Kermshlise C.
    Gusenleitner, Daniel
    Papenhausen, Gerald
    O'Connor, Niall
    Correll, Mick
    Quackenbush, John
    [J]. NUCLEIC ACIDS RESEARCH, 2012, 40 (D1) : D1060 - D1066
  • [10] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
    Denkert, Carsten
    von Minckwitz, Gunter
    Brase, Jan C.
    Sinn, Bruno V.
    Gade, Stephan
    Kronenwett, Ralf
    Pfitzner, Berit M.
    Salat, Christoph
    Loi, Sherene
    Schmitt, Wolfgang D.
    Schem, Christian
    Fisch, Karin
    Darb-Esfahani, Silvia
    Mehta, Keyur
    Sotiriou, Christos
    Wienert, Stephan
    Klare, Peter
    Andre, Fabrice
    Klauschen, Frederick
    Blohmer, Jens-Uwe
    Krappmann, Kristin
    Schmidt, Marcus
    Tesch, Hans
    Kuemmel, Sherko
    Sinn, Peter
    Jackisch, Christian
    Dietel, Manfred
    Reimer, Toralf
    Untch, Michael
    Loibl, Sibylle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 983 - 991